Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
6.68
+0.21 (3.25%)
May 13, 2025, 4:00 PM - Market closed
Company Description
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom.
Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases.
The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research.
Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Atara Biotherapeutics, Inc.
| Country | United States |
| Founded | 2012 |
| IPO Date | Oct 16, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 153 |
| CEO | Anhco Nguyen |
Contact Details
Address: 1280 Rancho Conejo Blvd Thousand Oaks, California 91320 United States | |
| Phone | 805 623 4211 |
| Website | atarabio.com |
Stock Details
| Ticker Symbol | ATRA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001604464 |
| CUSIP Number | 046513107 |
| ISIN Number | US0465131078 |
| Employer ID | 46-0920988 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Anhco Nguyen Ph.D. | President, Chief Executive Officer and Director |
| Yanina Grant-Huerta | Chief Accounting Officer and Principal Accounting Officer |
| Alex Chapman | Vice President of Corporate Communications and Investor Relations |
| Rajani Dinavahi M.D. | Senior Vice President and Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 12, 2025 | 8-K | Current Report |
| May 6, 2025 | 8-K | Current Report |
| Apr 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 28, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 4, 2025 | 8-K | Current Report |
| Mar 31, 2025 | 8-K | Current Report |
| Mar 7, 2025 | 10-K | Annual Report |
| Mar 7, 2025 | 8-K | Current Report |
| Mar 3, 2025 | 144 | Filing |
| Mar 3, 2025 | 144 | Filing |